Prognostic Impact of a Decrease in Serum Carbohydrate Antigen 19-9 Levels After Preoperative Therapy for 4 Months or More for Borderline Resectable Pancreatic Cancer Abutting Major Arteries
The American Surgeon™ · 2025
DOI: 10.1177/00031348241278016 ↗Kurz gefasst
Fachartikel in der Zeitschrift The American Surgeon™, 2025. Verfasst von Michinori Matsumoto und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, The Jikei University School of Medicine, Minato-ku, Tokyo. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, CA-19-9 Antigen, Pancreatectomy. Die Arbeit nennt 22 Literaturangaben. Gefördert von: Princess Takamatsu Cancer Research Fund, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Background
This study aimed to identify the prognostic factors after pancreatectomy for borderline resectable pancreatic cancer abutting major arteries (BR-A).
Methods
We retrospectively investigated relationship between preoperative and intraoperative variables and overall survival (OS) through univariate and multivariate analyses. The cut-off points of preoperative therapy duration and response rates of serum carbohydrate antigen 19-9 (CA19-9) levels after preoperative therapy were determined through a minimum P-value approach using the log-rank test for OS. Overall survival was compared among patients stratified according to the independent prognostic factors and the presence or absence of pancreatectomy.
Results
After pretreatment, 17 patients underwent pancreatectomy and four patients continued chemotherapy without surgery. Multivariate analysis in 17 resected BR-A patients demonstrated decreased serum CA19-9 levels and preoperative therapy duration of ≥4 months were the independent prognostic factors [hazard ratio (HR) 0.01; P = 0.002, HR 0.13; P = 0.02]. Patients who underwent surgery with decreased serum CA19-9 levels after preoperative therapy of ≥4 months had a significantly better prognosis than those without one or both of independent prognostic factors and those who did not undergo surgery (median survival time: not estimated, 23.3 months, 10.5 months, and 10.8 months; P = 0.02, P = 0.004, and P = 0.001, respectively). Furthermore, the prognosis did not significantly differ between the patients who underwent surgery without meeting either one or both criteria and those without surgery.
Conclusions
Preoperative therapy duration of ≥4 months and decreased serum CA19-9 levels are independent prognostic factors among BR-A patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, The Jikei University School of Medicine, Minato-ku, Tokyo.
- Department of Digestive surgery, Saku Central Hospital Advanced Care Center, Saku-shi, Nagano.
- Department of Surgery, Jikei University Daisan Hospital, Komae-shi, Tokyo.
ORCID-Profile: Michinori Matsumoto, Masashi Tsunematsu, Koichiro Haruki
Förderung
- Princess Takamatsu Cancer Research Fund
- Japan Society for the Promotion of Science
Zitieren
APA
Matsumoto, M., Tsunematsu, M., Abe, K., Hamura, R., Onda, S., Furukawa, K., Haruki, K., Okamoto, T., Uwagawa, T., & Ikegami, T. (2025). Prognostic Impact of a Decrease in Serum Carbohydrate Antigen 19-9 Levels After Preoperative Therapy for 4 Months or More for Borderline Resectable Pancreatic Cancer Abutting Major Arteries. The American Surgeon™. https://doi.org/10.1177/00031348241278016
Vancouver
Matsumoto M, Tsunematsu M, Abe K, Hamura R, Onda S, Furukawa K, et al. Prognostic Impact of a Decrease in Serum Carbohydrate Antigen 19-9 Levels After Preoperative Therapy for 4 Months or More for Borderline Resectable Pancreatic Cancer Abutting Major Arteries. The American Surgeon™. 2025. doi:10.1177/00031348241278016
BibTeX
@article{Matsumoto2025,
author = {Matsumoto, Michinori and Tsunematsu, Masashi and Abe, Kyohei and Hamura, Ryoga and Onda, Shinji and Furukawa, Kenei and Haruki, Koichiro and Okamoto, Tomoyoshi and Uwagawa, Tadashi and Ikegami, Toru},
title = {Prognostic Impact of a Decrease in Serum Carbohydrate Antigen 19-9 Levels After Preoperative Therapy for 4 Months or More for Borderline Resectable Pancreatic Cancer Abutting Major Arteries},
journal = {The American Surgeon™},
year = {2025},
doi = {10.1177/00031348241278016}
}
EUVIMED